Calendario›REGN›ALN-6457

ALN-6457

A Trial of ALN-6457 in Adult Participants With Symptomatic Prion Disease (PrD)

Ensayo de REGENERON PHARMACEUTICALS, INC. en Prion Disease (del registro, en inglés).

Fase

Fase 1/2

Estado

Aún sin reclutar

Participantes

60

previstos

Fin del objetivo primario

feb 2031

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, no aleatorizado, abierto. Comenzó en oct 2026.

Qué mide

Occurrence of Treatment Emergent Adverse Events (TEAEs) (Through Week 156) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study will test a Regeneron drug called ALN-6457 ("study drug") to see if it can help treat Prion Disease (PrD). In PrD, the prion protein folds into an abnormal shape. These abnormal proteins build up in the brain and cause damage to brain cells, leading to problems with thinking, memory, and movement. ALN-6457 is designed to reduce the amount of prion protein made in the brain. ALN-6457 works by targeting the genetic "instructions" that cells use to produce this protein, with the goal of slowing or stopping disease progression. This study is looking at: * What side effects ALN-6457 might cause * How well ALN-6457 works * What is the best dose of ALN-6457 for treating prion disease * How much ALN-6457 is in the blood and Cerebrospinal Fluid (CSF, fluid that surrounds the brain and spinal cord) at different times

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07832370), actualizada en sep 2026.